Merck to develop USD 1.3 billion research center in London by 2025

By Nikita Chaurasia  Date: 2020-08-19

Merck to develop USD 1.3 billion research center in London by 2025

America-based leading pharmaceutical company Merck & Co. Inc. (MSD) is reportedly moving ahead with its plans of building a research center in London. Sources close to the matter stated that the new facility, which will be known as London Discovery Research Centre, is valued at USD 1.3 billion and is estimated to be operational by the year 2025.

The project was initially announced in 2017 as a part of Merck’s initiative to support Britain post-Brexit, although it was delayed owing to the limitations in finding adequate space in the city, sources claimed. In addition to this, Merck intends to build its life sciences center near the Francis Crick Institute in the northern part of London.

However, the deal is yet to be finalized since it apparently requires the approval of London Borough of Camden. If sources are to be believed, work on the research center is anticipated to start late in 2021, with the facility providing over 120 jobs for technicians as well as researchers.

It appears that the site will be around 25,000 square meters and Merck intends to hire around 800 staff. Sources further stated that the research teams at the site will conduct early-stage diagnostics and majorly focus on age-related disorders.

MSD Managing Director for Ireland and UK, David Peacock, was reported saying that the company views the United Kingdom as a leader in developing science, which is primarily driven by the country’s long-term focus on developing a robust R&D infrastructure.

It is to be noted that Merck had entered a five-year joint venture agreement with Crick Institute to promote research & development in neuroscience. Although Merck’s research projects were conducted independently, the team was completely integrated into the scientific community of Crick Institute.

In fact, research teams from Merck and Crick collaborated in August 2019, in an effort to analyze the cause of Motore Neurone Disease, which was the first combined project since the initial five-year partnership.

Source Credits –

https://www.biospace.com/article/merck-to-build-1-31-billion-research-hub-in-london/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

By Nikita Chaurasia

Information technology giants Infosys, Accenture India, and Tata Consultancy Services will reportedly cover Covid-19 vaccination costs for their employees and their family, who are eligible and opt to receive the jab. This news comes along the heels...

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

By Nikita Chaurasia

Motorola Solutions has announced to have been selected by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to offer the Norwegian Health Emergency Service with a new CRS (Command Central Control Room Solution). Confirming the news,&...

Nestle India exploring options to directly sell products to consumers

Nestle India exploring options to directly sell products to consumers

By Nikita Chaurasia

Nestle India Ltd. is reportedly exploring their options of trying their hands at direct selling since consumers are largely turning towards the internet to purchase products ranging from staples to medicines amidst the COVID-19 pandemic. While the n...

Razorpay: New funding en route, meteoric rise in market value expected

Razorpay: New funding en route, meteoric rise in market value expected

By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge

FDA to allow pharma companies modify COVID-19 shots amid variants surge

By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...